{"success":true,"data":{"pressRelease":{"id":"74668","rtpr_id":"nNFC4Fcdw3","ticker":"TELO","exchange":"","all_tickers":["TELO"],"title":"Telo Genomics Announces Termination of Investor Relations Agreement","author":"Newsfile Corp","published_at":"2026-06-27T00:57:55.265Z","article_body":"Vancouver, British Columbia--(Newsfile Corp. - June 26, 2026) - Telo Genomics\nCorp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"Telo Genomics\"), a leader\nin the development of diagnostic and prognostic tests for human disease\nthrough the analysis of chromosomal telomeres, announces that the investor\nrelations consulting agreement with Sheridan Adams, LLC (\"Sheridan\"), as\nannounced on March 31, 2026, has been terminated effective June 12, 2026. It\nwas initially understood between the parties that this was a transitory role\nfor Sheridan and was not intended to be long term. The Company wishes Sheridan\nwell with its future endeavours.\n\nAbout Telo Genomics\n\nTelo Genomics is a biotech company pioneering the most comprehensive telomere\nplatform in the industry with powerful applications and prognostic solutions.\nThese include liquid biopsies and related technologies in oncology and\nneurological diseases. Liquid biopsy is a rapidly growing field of significant\ninterest to the medical community for being less invasive and more easily\nreplicated than traditional diagnostic approaches. By combining our team's\nconsiderable expertise in quantitative analysis of 3D telomeres with molecular\nbiology and artificial intelligence to recognize disease associated genetic\ninstability, Telo Genomics is developing simple and accurate products that\nimprove day-to-day care for patients by serving the needs of pathologists,\nclinicians, academic researchers and drug developers. The benefits of our\nproprietary technology have been substantiated in 160+ peer reviewed\npublications and in 30+ clinical studies involving more than 3,000 patients\nwith multiple cancers and Alzheimer's disease. Our lead application, Telo-MM\nis being developed to provide important, actionable information to medical\nprofessionals in the treatment of Multiple Myeloma, a deadly form of blood\ncancer. For more information, please visit www.telodx.com.\n\nFor further information, please contact:\nJohn Price\nChief Financial Officer\n408-550-5767\ninfo@telodx.com\n\n555 Richmond Street West\nToronto, ON, Canada, M5V 3B1\nwww.telodx.com\n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as such\nterm is defined in the policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nCautionary Note Regarding Forward-Looking Statements\n\nCertain information contained herein may constitute \"forward-looking\ninformation\" under Canadian securities legislation. Generally, forward-looking\ninformation can be identified by the use of forward-looking terminology such\nas \"intends\", or variations of such words and phrases or statements that\ncertain actions, events or results \"will\" occur. Forward-looking statements\nare subject to known and unknown risks, uncertainties and other factors that\nmay cause the actual outcome to be materially different from those expressed\nor implied by such forward-looking statements or forward-looking information.\nThere can be no assurance that such statements will prove to be accurate, as\nactual results and future events could differ materially from those\nanticipated in such statements. Accordingly, readers should not place undue\nreliance on forward-looking statements and forward-looking information. The\nCompany will not update any forward-looking statements or forward-looking\ninformation that are incorporated by reference herein, except as required by\napplicable securities laws.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/303174","article_body_html":"","raw_payload":{"data":{"id":"nNFC4Fcdw3","title":"Telo Genomics Announces Termination of Investor Relations Agreement","author":"Newsfile Corp","ticker":"TELO","created":"2026-06-27T00:57:55.265Z","tickers":["TELO"],"exchange":"","article_body":"Vancouver, British Columbia--(Newsfile Corp. - June 26, 2026) - Telo Genomics\nCorp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"Telo Genomics\"), a leader\nin the development of diagnostic and prognostic tests for human disease\nthrough the analysis of chromosomal telomeres, announces that the investor\nrelations consulting agreement with Sheridan Adams, LLC (\"Sheridan\"), as\nannounced on March 31, 2026, has been terminated effective June 12, 2026. It\nwas initially understood between the parties that this was a transitory role\nfor Sheridan and was not intended to be long term. The Company wishes Sheridan\nwell with its future endeavours.\n\nAbout Telo Genomics\n\nTelo Genomics is a biotech company pioneering the most comprehensive telomere\nplatform in the industry with powerful applications and prognostic solutions.\nThese include liquid biopsies and related technologies in oncology and\nneurological diseases. Liquid biopsy is a rapidly growing field of significant\ninterest to the medical community for being less invasive and more easily\nreplicated than traditional diagnostic approaches. By combining our team's\nconsiderable expertise in quantitative analysis of 3D telomeres with molecular\nbiology and artificial intelligence to recognize disease associated genetic\ninstability, Telo Genomics is developing simple and accurate products that\nimprove day-to-day care for patients by serving the needs of pathologists,\nclinicians, academic researchers and drug developers. The benefits of our\nproprietary technology have been substantiated in 160+ peer reviewed\npublications and in 30+ clinical studies involving more than 3,000 patients\nwith multiple cancers and Alzheimer's disease. Our lead application, Telo-MM\nis being developed to provide important, actionable information to medical\nprofessionals in the treatment of Multiple Myeloma, a deadly form of blood\ncancer. For more information, please visit www.telodx.com.\n\nFor further information, please contact:\nJohn Price\nChief Financial Officer\n408-550-5767\ninfo@telodx.com\n\n555 Richmond Street West\nToronto, ON, Canada, M5V 3B1\nwww.telodx.com\n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as such\nterm is defined in the policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nCautionary Note Regarding Forward-Looking Statements\n\nCertain information contained herein may constitute \"forward-looking\ninformation\" under Canadian securities legislation. Generally, forward-looking\ninformation can be identified by the use of forward-looking terminology such\nas \"intends\", or variations of such words and phrases or statements that\ncertain actions, events or results \"will\" occur. Forward-looking statements\nare subject to known and unknown risks, uncertainties and other factors that\nmay cause the actual outcome to be materially different from those expressed\nor implied by such forward-looking statements or forward-looking information.\nThere can be no assurance that such statements will prove to be accurate, as\nactual results and future events could differ materially from those\nanticipated in such statements. Accordingly, readers should not place undue\nreliance on forward-looking statements and forward-looking information. The\nCompany will not update any forward-looking statements or forward-looking\ninformation that are incorporated by reference herein, except as required by\napplicable securities laws.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/303174"},"type":"article","timestamp":"2026-06-27T00:57:55.319181197Z","server_sent_at_ms":1782521875319},"received_at":"2026-06-27T00:57:55.369Z","source_url":"https://www.newsfilecorp.com/release/303174"},"analysis":{"id":"64027","press_release_id":"74668","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Telo Genomics has terminated its investor relations consulting agreement with Sheridan Adams, LLC, effective June 12, 2026.\n\nThe company characterized the engagement as a transitory role that was not intended to be long term.\n\nTelo Genomics continues to develop its telomere analysis platform, including the Telo-MM liquid biopsy application for Multiple Myeloma.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine vendor change with no material business impact."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[{"name":"John Price","role":"Chief Financial Officer"}],"products":["Telo-MM"],"companies":[{"name":"Sheridan Adams, LLC","relationship":"former investor relations firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine termination of an investor relations consulting agreement. The company explicitly states the role was intended to be transitory, indicating no underlying distress or operational pivot."},"tickerRelevance":{"others":[{"ticker":"TDSGF","relevance":"mentioned"}],"primary":"TELO"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"vendor_termination","sectorWeight":"biotech"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Telo Genomics has terminated its investor relations consulting agreement with Sheridan Adams, LLC, effective June 12, 2026.\n\nThe company characterized the engagement as a transitory role that was not intended to be long term.\n\nTelo Genomics continues to develop its telomere analysis platform, including the Telo-MM liquid biopsy application for Multiple Myeloma.","key_figures":null,"named_entities":{"people":[{"name":"John Price","role":"Chief Financial Officer"}],"products":["Telo-MM"],"companies":[{"name":"Sheridan Adams, LLC","relationship":"former investor relations firm"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-27T00:59:00.876Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"micro-cap","eventGravity":"vendor_termination","sectorWeight":"biotech"}},"durationMs":65491,"modelName":"george-droid-qwen-72b"}}